Compare Tango Therapeutics Inc. (TNGX) vs Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) (UGP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B), while Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) trades at $7.68 (market cap $8.29B). The key difference: Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) is far larger — about 2.2× Tango Therapeutics Inc.'s market cap, and Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) pays a 4.82% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) for 3 Days on average.
| TNGX | UGP | |
|---|---|---|
Market Cap | $3.75B | $8.29B |
Volume | 9,619,106 | 3,910,942 |
Sector | Health | Energy |
52-Week High | $32.90 | $7.90 |
52-Week Low | $7.50 | $3.63 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $2.77B | $10.36B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
UGP trades at $7.79, down 1.27% today but near recent 52-week highs. The stock shows strong technical momentum with bullish moving averages and solid fundamentals including 20.32% ROE and attractive valuation metrics (P/E 11.86, EV/EBITDA 5.1). Recent earnings beat expectations in Q2 2026 with $0.28 EPS versus $0.27 expected. The company demonstrated strong cash flow generation with $5.45B from operations in 2025, supporting its growth investments and financial discipline strategy outlined at recent investor events.
UGP presents a compelling value opportunity with improving profitability margins and revenue growth projected to reach $153.3B in 2026. However, risks include competitive pressures in oil and gas distribution, margin compression from rising costs, and dependence on energy price stability. Analyst consensus remains cautiously optimistic with 36% buy ratings but a $6.85 price target below current levels, suggesting potential near-term consolidation before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share)
Ultrapar is a Brazilian company with fuel distribution, liquefied petroleum gas, and chemical businesses. Its consumer-facing operations include fuel and gas distribution brands.
Read more on UGP →
